This review includes three studies with a total of 1104 participants. We excluded two large important studies because they did not report any usable data. The three that were included suggested that sertindole (20 mg/day) was more antipsychotic than placebo, as acceptable as placebo (in terms of various adverse events including movement disorde r s and somnolence) and better tole r ated than haloperidol. Sertindole was associated with fewer movement disorders than h aloperidol, but was shown to cause more weight gain
and the possible side e ffect of male sexual dysfunction. Cardiac problems (QTc intervals of at least 500 msec) were evident even in the randomised trials. Sertindole used at 16 mg/day (reported to be the most optimal dose by one study) caused more rhinitis than haloperidol.